• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsCorporate GovernanceGeneral meeting

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

General meeting

Annual General Meeting 2021

The Annual General Meeting will be held on the May 4, 2021 in Stockholm.

Shareholders who wish to have a matter addressed at a general meeting must submit a request in writing to the Board of Directors. The request should, under normal circumstances, reach the Board of Directors by no later than seven weeks before the meeting. However, any shareholder who submits a matter sufficiently in advance that the matter can be included in the notice to the general meeting is entitled to have the matter addressed at the general meeting. Shareholders who wish to have a matter addressed at the Annual General Meeting, please contact the Board of Directors of Immunicum via mail to: The Board of Directors, Immunicum AB (publ), Östermalmstorg 5, SE-114 42 Stockholm, Sweden, or e-mail: info@immunicum.com.

Extraordinary General Meeting in Immunicum AB (publ) 2021

The Extraordinary General Meeting will take place on January 22, 2021 at 13:00 at IVA’s Conference Center at Grev Turegatan 16 in Stockholm.

Immunicum cherish both its shareholders’ well-being as their opportunity to attend the Extraordinary General Meeting to exercise their rights as shareholders. In order to reduce the risk of spreading the covid-19, shareholders are offered the opportunity to vote through proxy at the general meeting or exercise their voting rights via mail before the general meeting. Please refer to the notice for further information regarding notification to the general meeting and for the opportunity to vote through proxy or via mail.

Shareholders who are ill or belong to a risk group should not participate, but are recommended to vote through proxy or via mail.

NOTIFICATION
Shareholders who wish to attend the meeting shall:
(i) be recorded in the share register maintained by Euroclear Sweden AB on the record date of Thursday, January 14, 2021, and

(ii) not later than on Monday, January 18, 2021 have notified their attendance and any advisors to the Company; either in writing via letter to Immunicum AB (publ), “General meeting”, Östermalmstorg 5, SE-114 42 Stockholm or by e-mail to info@immunicum.com.

Title Type
Notice of Extraordinary General Meeting 2021 pdf
Power of Attorney form pdf
Power of Attorney form incl. voting instructions pdf
Form for postal voting pdf
Proposal for election of new board members pdf
Minutes from EGM (Swedish) pdf

Extraordinary General Meeting in Immunicum AB (publ) 2020

The Extraordinary General Meeting will take place on December 18, 2020 at 13:00 at IVA’s Conference Center at Grev Turegatan 16 in Stockholm.

Immunicum cherish both its shareholders’ well-being as their opportunity to attend the Extraordinary General Meeting to exercise their rights as shareholders. In order to reduce the risk of spreading the covid-19, shareholders are offered the opportunity to vote through proxy at the general meeting or exercise their voting rights via mail before the general meeting. Please refer to the notice for further information regarding notification to the general meeting and for the opportunity to vote through proxy or via mail.

Shareholders who are ill or belong to a risk group should not participate, but are recommended to vote through proxy or via mail.

NOTIFICATION
Shareholders who wish to attend the meeting shall:

  1. be recorded in the share register maintained by Euroclear Sweden AB on the record date of Thursday, 10 December 2020, and
  1. not later than on Monday, 14 December 2020 have notified their attendance and any advisors to the Company; either in writing via letter to Immunicum AB (publ), “General meeting”, Östermalmstorg 5, SE-114 42 Stockholm or by e-mail to info@immunicum.com.
Title Type
Notice of Extraordinary General Meeting 2020 pdf
Form for postal voting pdf
Power of Attorney form pdf
Power of Attorney form incl. voting instructions pdf
Board's report regarding events of material significance pdf
Board's report regarding the contribution in kind pdf
Board's resolution on issue in kind pdf
Auditor's statement regarding the contribution in kind pdf
Auditor's statement regarding events of material significance pdf
Item 6. Board's proposal for amendment of the articles of association pdf
Item 7. Board's proposal for approval of issue in kind pdf
Item 8. Board's proposal for authorization to the board pdf
New articles of assocation pdf
Minutes from EGM (Swedish) pdf

Annual General Meeting 2020

The Annual General Meeting 2020 will take place on April 28, 2020 at 10:30 at the IVA Conference Center at Grev Turegatan 16, Stockholm.

Immunicum cherish both its shareholders’ well-being as their opportunity to the Annual General Meeting to exercise their rights as shareholders. In order to reduce the risk of spreading the virus covid-19 (the corona virus), Immuncium will hold a short and effective annual general meeting in order to limit the contacts between the participants.

As part of this, no food is served to the participants. Employees in the company who are ill or have been at risk will not be present in the premises.

Shareholders who are ill, have recently resided in a risk area or belong to a risk group should not participate, but are recommended to vote through a representative.

Title Type
Notice to AGM 2020 pdf
Power of attorney form pdf
Boards report pursuant to rule 10.3 of the Code pdf
Item 7b The Board of directors proposal regarding allocation of results pdf
Item 11 Proposal regarding guidelines for remuneration to senior executives pdf
Item 12 The Board's proposal to amend the incentive program LTI 2019_2022 pdf
Item 13 Proposal for authorization for the board of directors pdf
Auditor's opinion on remuneration to senior executives pdf
The Board's statement according to Act 19 22 pdf
Matters submitted by the shareholder Creopretium AB pdf
Minutes from AGM (Swedish) pdf

Annual General Meeting 2019

Title Type
Notice to AGM 2019 pdf
Power of attorney form pdf
Board report pursuant to rule 10.3 of the Code pdf
Item 7b The Board of directors proposal regarding allocation of results pdf
Item 11 Proposal regarding guidelines for remuneration pdf
Item 12 Proposal amending the AoA pdf
Item 13 Proposal for incentive program pdf
Item 14 Proposal regarding authorization for the board of directors pdf
Auditor's statement (in Swedish) pdf
Terms and conditions for warrants pdf

Extraordinary General Meeting 2018

Title Type
Notice to EGM pdf
Board resolution on directed share issue pdf
Board proposal for resolution on directed share issue pdf
Board resolution on rights issue pdf
Board proposal for resolution on rights issue pdf
Board’s report pdf
Auditor’s statement (in Swedish) pdf
Power of Attorney form pdf
Minutes from EGM (Swedish) pdf

Annual General Meeting 2018

Notice of annual general meeting and additional attachments are found below.

Title Type
Notice of Annual General Meeting pdf
Item 7 - The board of directors complete proposal regarding allocation of results pdf
Item 11 - Guidelines for renumeration of senior management pdf
Item 12 - Change of articles of association pdf
Item 13 - authorization new issue pdf
The board of directors' evaluation pursuant to rule 10.3 of the Code pdf
The auditor's opinion under chapter 8 section 54 of the Swedish Companies Act pdf
Power of attorney AGM pdf

General meeting

In accordance with the Companies Act, is the shareholders’ influence in Immunicum exercised at the general meeting, which is the company’s highest ranking decision-making body. At the annual general meeting, the shareholders decide upon central matters, including amendments of the articles of association, confirmation of the income statements and balance sheets, possible dividends and distribution of the company’s profit or loss, election of board members and auditors and decisions regarding remuneration to the same, and decision regarding discharge of liability for the board of directors and the managing director.

In accordance with the articles of association, the notice of summons to annual general meeting shall be made by announcement in Post- och Inrikes Tidningar and by making the notice of summons available on the company’s website. Simultaneously with the notice, the company shall by way of announcement in Dagens Industri inform that notice has been made. Notice of summons to the annual general meeting and an extraordinary general meeting where a matter of amendment of the articles of association shall be resolved shall be made at earliest six (6) and not later than four (4) weeks prior the meeting. Notice of summons to other extraordinary general meetings shall be made at earliest six (6) and not later than three (3) weeks prior to the extraordinary general meeting.
Shareholders recorded in the share register in accordance with the provisions in the Companies Act, and that have given notice of their attendance to the company no later than the day mentioned in the notice, have the right to participate at the general meeting. Such day may not be on a Sunday, any other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth working day prior to the meeting.

At the annual general meeting, the following matters shall be addressed:

1. Election of chairman of the general meeting.

2. Preparation and approval of voting register.

3. Presentation and approval of the agenda.

4. Election of one or two persons to check the minutes.

5. Control if the meeting has been duly convened.

6. Presentation of the annual report and the audit report and, if applicable, the consolidated annual report and consolidated audit report.

7. Decisions
a) on confirmation of the income statement and balance sheet and, if applicable, the group income statement and group balance sheet.
b) on disposition of the company’s profit or loss according to the adopted balance sheet.
c) discharge of liability for the board of directors and the managing director.

8. Determination of remuneration for the directors of the board of directors and auditors.

9. Election of directors of the board of directors and auditors and, if applicable, deputy auditors.

10. Other matters that are to be addressed at the annual general meeting pursuant to the Companies Act or the articles of association.

 


Extraordinary General Meeting 2017

Notice of extraordinary general meeting and additional attachments are found below.

Title Type
Meeting minutes (in Swedish) pdf
Notice of extraordinary general meeting pdf
Power of attorney form pdf
Proposed resolution of amendment of articles of association pdf
Proposed resolution - approval of rights issue pdf
Board resolution - rights issue pdf
13.6 - board of director's statement pdf
13.6 - Auditor's statement (in Swedish) pdf

Annual General Meeting 2017

Title Type
Notice of summons 2017 pdf
Proxy Form (Swedish only) pdf
Nomination Committee Statement (Swedish only) pdf
The board of directors' proposal regarding authorization (Swedish only) pdf
The board of directors' proposal regarding guidelines for remuneration to senior executives (Swedish only) pdf
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve